Toggle navigation
- Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
Voir le communiqué de presse
- Q1 2003 Financial Information (IN FRENCH).
Voir le communiqué de presse
- Limagrain starts its recruitment campaign! 600 seasonal crops are expected for its summer and autumn harvests (IN FRENCH).
Voir le communiqué de presse
- Valbiotis announces its Combined Shareholders General Meeting will be held on May 2, 2023.
Voir le communiqué de presse
- The pharmaceutical site of Riom La Varenne for 10 years within the SMO Biopôle Clermont-Limagne (IN FRENCH).
Voir le communiqué de presse
- F22 – 2023 beginnings and Outlook (IN FRENCH).
Voir le communiqué de presse
- Valbiotis announces the last visit of the last patient in the Phase II/III REVERSE-IT study on TOTUM•63, in partnership with Nestlé Health Science.
Voir le communiqué de presse
- 2022 turnover: €226.6 million (IN FRENCH).
Voir le communiqué de presse
- Approval of the agreement concluded by METabolic EXplorer with its main partners on 23 December 2022 under the conciliation procedure (IN FRENCH).
Voir le communiqué de presse
- Inauguration of the new production unit of CARBOGEN AMCIS SAS at Biopôle Clermont-Limagne (Saint-Beauzire, Puy de Dôme) Friday, February 3, 2023 (IN FRENCH).
Voir le communiqué de presse
